Introduction
The relatively small number of new drugs developed in recent years is a cause for concern. The number of new molecular entities, drugs targeted to novel molecular sites and thus with a possible disease-modifying property, has decreased from 52 in 1996 to 12 in 2005 [1] . This is in contrast to the doubling in R&D expenses during the same period [2] . Hopes that the sequencing of the human genome would expedite the process of drug discovery were disproved. Although the combination of the human genome project with powerful computational techniques can theoretically identify new genes encoding for possible drug targets, and is now being applied to the drug discovery process [3] , the desired increase in approvals has not been met. Overall, the reduced number of new molecular entities has a great impact on the price of new drugs [1, 2, 4] . Treatment of central nervous system (CNS) inflammation poses an even more difficult challenge, due to the need for the active molecule to penetrate the blood-brain barrier and act within the CNS.
Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Our approach to the development of novel treatment for autoimmune neuroinflammation is based on experiments in the animal model of multiple sclerosis (MS), i.e., experimental autoimmune encephalomyelitis (EAE). EAE is an inflammatory demyelinating autoimmune disease of the CNS. Since the disease is induced by a known antigen, study of the pathogenesis of EAE has led to many immunological insights, allowing lessons from EAE to be generalized and applied to other autoimmune diseases [5] . Experiments in EAE led to the development of several approved drugs for MS and the model has been useful in helping us to understand the disease. It was found that the inflammatory process in EAE and MS involves extravasation of activated T cells through blood vessels and activation of CNS immunocompetent cells, which accumulate at the inflammatory sites. The initial inflammatory phase is followed by a phase of selective demyelination and, finally, neurodegeneration [6, 7] . The latter is mainly characterized by axonal injury, which begins at disease onset and correlates with the degree of inflammation within lesions. A threshold of axonal loss must be exceeded before irreversible neurological disability occurs [8] . In spite of the marked progress in the assessment and therapy of MS, there is a need for improved therapy that will halt disease progression and lead to reversal of the neurological disability.
Treatment of Neuroinflammation with Bifunctional Compounds Eliciting Both Anti-Inflammatory and Cholinergic Activity
The design of these molecules is based on a combination of two different pharmacologically active entities in one molecule. One moiety is a non-steriodal anti-inflammatory drug (NSAID, e.g. ibuprofen, diclofenac, naproxen or indomethacin), the other is either an acetylcholinesterase (AChE) inhibitor or a cholinergic agonist. These two moieties are coupled by a hydrocarbon chain spacer which contains 8-10 carbon atoms that enhances the lipophilicity of the active moieties and provides better penetration through the blood-brain barrier. Some of these bifunctional compounds (e.g. ibuprofen-octyl-pyridostigmine, IBU-PO) reduced lesion volume and limited neuronal injury in closed head injury and increased survival in hypobaric hypoxia [9] . In another study, IBU-PO inhibited, at submicromolar concentrations, the toxicity exerted by ␤ -amyloid peptide on neuronal rat brain cells by acting as a glycogen-synthase-kinase-3 ␤ (GSK-3 ␤ ) inhibitor [10] . As the bifunctional molecules showed promising results in these settings, in which there is a prominent inflammatory component, we tested these compounds in EAE. Moreover, as EAE is a complex inflammatory process involving various active cells and immunological damage mechanisms, we thought it would be useful to target different cascades in its pathogenesis. Recent data question the strategy of drug selectivity, i.e. drugs designed to interact with a single molecular entity, and call for molecules that will address several molecular targets [11] . Single targets proved inefficient in many cases because of biological redundancy: meaningful physiological and pathological processes are not dependent solely on one molecular target. Indeed, it was shown that combination therapy in EAE was more effective than either of the treatments alone, and that multiple treatment regimens cannot only prevent damage in animals but may even reverse it [12] . This was our primary incentive in the use of bifunctional molecules. We tested two bifunctional compounds, IBU-PO and IBU-PD, composed of a NSAID moiety, ibuprofen (IBU), and a cholinergic moiety, the AChE inhibitor pyridostigmine (pyridostigmine octyl-PO, pyridostigmine decyl-PD, respectively) [13] . The two compounds differ in the length of the hydrophobic hydrocarbon spacer connecting the two moieties. IBU-PD, in which the spacer spans ten carbon atoms, is more hydrophobic than IBU-PO, which contains a hydrocarbon spacer consisting of eight carbon atoms ( fig. 1 a, b) . Consequently, IBU-PD is better able to penetrate the CNS. IBU can ameliorate EAE through cyclooxygenase (COX)-dependent mechanisms, i.e. inhibition of arachidonic acid metabolite formation [14] . IBU was previously shown to reduce the production of insoluble ␤ -amyloid peptide although not by COX inhibition [15] . IBU also reduced NF-B transcription activity by a non-COX-dependent mechanism [16] . This reduction can influence the expression of iNOS and COX-2 [17] , thus lowering NO and PGE 2 production, respectively. In addition, it was shown that other NSAIDs reduced TNF-␣ production in the CNS [18] , a finding particularly relevant to our bifunctional compound, which was designed to act in the CNS. The cholinergic moiety in the bifunctional compounds leads to the activation of the ␣ 7 nicotinic acetylcholine receptor (nAChR) in immune cells. Anti-inflammatory properties were attributed to this receptor in macrophages [19] and lymphocytes [20] . We have shown that AChE inhibitor may activate this anti-inflammatory receptor by slowing ACh breakdown and thus increasing the number of potential endogenous ligands [20] . Therefore, the use of the bifunctional molecules would allow the targeting of either the COX-dependent or COX-independent inflammatory cascade and of the cholinergic immune system, along with increased permeability into the CNS. We previously found that the molecular combination of the two functions in one molecule does not affect the inhibition of AChE or the inhibition of COX isoenzymes [9] .
Effects of the Bifunctional Molecules on Clinical Parameters of EAE, T-Cell Reactivity and the Inflammatory Response of CNS Resident Immunocompetent Cells
Treatment with both IBU-PO (1 mg/kg, i.p.) and IBU-PD (0.1 mg/kg, i.p.) from the day of EAE induction ameliorated the clinical outcome, as manifested here by a significant (30-40%) reduction in disease severity ( fig. 2 a) . Treatment with IBU (0.1 mg/kg) or PD (0.1 mg/kg) alone did not reduce the disease burden: the mean severity in the placebo control group was 1.9, and in the IBU-and PD-treated groups 1.9 and 2.1, respectively. The ineffectiveness of IBU under these conditions is attributable to its low dose and limited availability in the CNS (see below). The same pattern of synergistic effect achieved by the bifunctional compound and not by either of its components, was also observed in T-cell reactivity towards the encephalitogenic peptide myelin oligodendrocyte glycoprotein (MOG) that was used for disease induction [13] .
The effects of IBU-PO on activated astrocytes in primary culture were also studied, as these cells become ac- tivated in the inflamed CNS in general, and in EAE in particular. When stimulated by an inflammatory factor such as LPS or TNF-␣ , astrocytes produce various cytokines and inflammatory mediators, including PGE 2 . In this system, IBU-PO had a greater impact than IBU on PGE 2 production, although PO and also other AChE inhibitors tested had no effect ( fig. 2 b) . This finding indicated a novel and unexpected influence of the bifunctional compound. The addition of a second moiety augmented the effect of the active IBU moiety. This effect is not attributable merely to the increased permeability of IBU-PO, since IBU-octyl contains the hydrocarbon spacer responsible for enhanced lipophilicity, but is less active in PGE 2 suppression. Furthermore, we assume that cells are more permeable to IBU-octyl than to IBU-PO, since it does not contain the positively charged quaternary nitrogen present in pyridostigmine. The use of IBU-PO may possibly affect the cellular metabolism of the active substance, as no change was seen in COX inhibition by the bifunctional compound compared with that of IBUoctyl alone.
We tested another bifunctional molecule, IBU-octylcytisine ( fig. 1 c) , in which the cholinergic moiety is cytisine, a nicotinic agonist. This molecule was designed to interact directly with ␣ 7 AChR instead of inhibiting ACh breakdown. Our results show that daily treatment with IBU-octyl-cytisine (2.5 mg/kg, i.p.) markedly inhibited (by 70%) clinical and pathological parameters of EAE. The clinical score of animals treated with either of the moieties (i.e. IBU-octyl or cytisine, in equivalent doses) and of animals treated with both moieties unconjugated but mixed together in solution, was virtually the same as that of the control. Treatment with cytisine was severely toxic, with 80% mortality, yet none of the animals treated with the bifunctional compound showed any significant signs of toxicity.
The strategy in using bifunctional compounds rests on several assumptions: (1) The activity of each of the moieties is preserved in the bifunctional compounds.
(2) The utilization of multiple targets in the treatment of the pathologic process (EAE, in our case) is more efficient than treatment aimed at one target. (3) The effect of the bifunctional compound is superior to that of a non-conjugated mixture of the two active moieties, i.e., the use of bifunctional compounds is superior to conventional combination therapy. The data indeed show that careful selection of the appropriate active moieties allows preservation of the two activities. Treatment with either of the moieties or in a mixture was significantly less effective than treatment with the bifunctional molecules. Furthermore, the use of the bifunctional compounds changed the pharmacokinetics of the active moieties while preserving their pharmacodynamics. In addition, the unitary pharmacokinetics of the bifunctional compound mobilizes both moieties to the target at the same time. The activity of the IBU moiety in IBU-PO was augmented, whereas the toxicity of cytisine was diminished by IBU-octyl-cytisine. The use of the bifunctional compounds allowed a significant reduction in IBU dose. Previous reports on the beneficial effect of COX inhibitors on EAE dealt with a two orders of magnitude higher dose (200 mg/kg) [14] than in our study (0.1-1 mg/kg). A reduced dose of IBU is advantageous in chronic treatment in light of its adverse gastrointestinal and other side effects.
The significance of compliance and adherence to treatment in the clinical setting cannot be overemphasized [21] [22] [23] . Compliance may affect the treatment protocol and lead to disappointing clinical outcomes even if the drug is of proven biological efficacy. The use of bifunctional compounds can improve compliance in patients: not only can several drugs be taken in one pill, but the daily dosage can be decreased due to the altered metabolism of the new compound.
The moieties incorporated in our bifunctional compounds are known off-patent drugs. The use of such compounds allows accessibility to a large database regarding their pharmacologic profile. Since they have been approved and are in wide clinical use, specific receptor interactions, drug metabolism and excretion, adverse effects and dosage have been determined. Thus we suggest amplifying the efficacy of known drugs by the bifunctional combination strategy -a new way 'to teach old drugs new tricks' [24] .
Treatment of Autoimmune Neuroinflammation by the Natural Immunomodulating Protein ␣ -Fetoprotein
The strategy of endogenous/natural compounds as therapeutic agents has several advantages. Harnessing physiological mechanisms to achieve medical outcomes enjoys the efficacy of normal functioning. Once a hormonal cascade has been elucidated, each step can be deliberately used to achieve effectively a given purpose. Moreover, by mimicking the physiological environment, the toxicity of treatment is circumvented, as manifested by reduced side effects. The immunogenicity obstacle is also bypassed. A naturally active protein is readily available for the pharmaceutical industry, based on cloning and translational techniques. Clinical examples of this strategy are: treatment with follicular-stimulating hormone and luteinizing hormone for induction of superovulation in assisted reproduction [25] , growth hormone supplementation for developmental deficits [26] , etc. In addition, much research has been devoted to the immunomodulating activity of estrogen, a steroidal hormone present at high levels during pregnancy [27] . We here present a new application of this strategy, namely the use of ␣ -fetoprotein (AFP) to mimic the pregnancy-associated immune modulation.
Clinical remissions during the second half of pregnancy, as well as postpartum relapses, have been described in several autoimmune diseases, such as myasthenia gravis (MG), rheumatoid arthritis, thyroiditis and MS [28] [29] [30] [31] [32] . The suppressive effect of pregnancy on autoimmune conditions may be correlated with other immunological phenomena occurring during pregnancy, such as the immunosuppressive effect of both maternal serum and amniotic fluid on lymphocyte and antibody responses to mitogens and antigens [33, 34] , prolonged homograft survival of skin [35] , enhanced development of tumors [36] and increased susceptibility to infections [37, 38] . These immunological changes have been attributed to pregnancy-associated factors such as early pregnancy factor, placental protein 14, AFP, hormonal steroids, estrogens and progesterones, pre-implantation factor and pregnancy-specific glycoproteins [39] [40] [41] [42] . AFP is associated with the normal growth of the mammalian fetus. During fetal life, AFP is produced mainly by the embryonic yolk sac and liver. This serum glycoprotein, produced in high concentrations during embryonic and neonatal stages, tends to decline drastically as the organism matures.
We suggested that some of these observed immunomodulating effects on autoimmune diseases might be related to the high levels in the maternal serum of AFP [43] . Comprehensive research done in our laboratory, using human AFP isolated from amniotic fluid [33, 34, 43] , and recombinant human AFP isolated from Escherichia coli or from the milk of transgenic goats [44] , revealed broad immunomodulatory activity, influencing autoimmune disorders and inflammatory reactions. We have studied AFP in two major animals models, EAE and experimental autoimmune myasthenia gravis (EAMG). The latter serves as a model for MG and is an antibody-mediated autoimmune disease caused by specific antibodies to AChR at the neuromuscular junction.
Following AFP treatment (3-10 g/mouse/day, i.p.) a dramatic amelioration of all the clinical parameters of EAE was observed. The mean severity was reduced by 65-70%, as can be seen in figure 3 . This prominent effect was obtained in both C57BL and SJL mouse species. It appears that the suppressive in vivo effect of AFP was biphasic: complete protection in animals that did not show clinical symptoms, and partial protection of those that developed a milder disease. The clinical findings were consistent with the histological manifestation of CNS sections. Bielschowsky silver impregnation combined with hematoxylin staining revealed marked dystrophy and loss of axons, together with massive infiltration of mononuclear cells in EAE mice treated with PBS ( fig. 4 ) . Furthermore, treatment with recombinant human (rhAFP) markedly limited the inflammatory process and axonal pathology ( fig. 4 ) . rhAFP reduced the extent of axonal injury by 55%, from a mean value of 1.6 8 0.12 in the PBS-treated mice to 0.9 8 0.09 in the rhAFP-treated mice (scale: 0 = normal, 1 = scattered injured axons, 2 = mild to moderate axonal injury, 3 = severe axonal injury). Moreover, rhAFP limited the axonal loss by up to 85%, from a mean value of 0.5 8 0.06 in the PBS-treated mice to 0.1 8 0.06 in the rhAFP-treated mice (scale: 0 = normal, 1 = mild to moderate axonal T cells play a central role in the pathogenesis of EAE, both at the initial phase in the periphery and later as the inflammatory process becomes limited to the CNS. Influencing this arm of the immune response is of prime importance in the treatment of autoimmune disorders. In our study, treatment with AFP suppressed T-cell reactivity towards the MOG encephalitogenic peptide 35-55, as manifested by a significant reduction in the proliferation rate associated with lower secretion of IFN-␥ and TNF-␣ , both proinflammatory cytokines extensively involved in EAE and MS ( fig. 5 ). This ability of AFP may be related to the disrupted antigen presentation, manifested by downregulation of MHC class II expression, observed following treatment. The effect of AFP was restricted to activated lymphocytes, supporting previous studies that identified specific receptors for AFP on activated lymphocytes but not on resting cells [45, 46] . Moreover, following treatment with AFP there was a decline of 57% in the number of lymphocytes expressing the chemokine receptor CCR5, which mediates extravasation of inflammatory cells from the circulation into the CNS through the blood vessel endothelial wall. Thus, by reducing their proliferation and altering CCR5 expression, AFP can prevent the organ-specific migration of encephalitogenic T cells to the CNS, as well as ameliorate local inflammation. The beneficial effect of AFP on CNS inflammation and demyelination may also be attributed to its ability to suppress the production of myelin-specific antibodies which are also involved in the immune cascade leading to axonal damage. Indeed, a 60 and 70% reduction in MOG-specific IgM and IgG antibodies, respectively, was observed following rhAFP treatment. The ability of AFP to regulate immune reactions was not restricted to EAE. Treatment with AFP of EAMG Lewis rats improved the clinical outcome of the animals. We conclude that the embryo-specific glycoprotein AFP induces a spectrum of immunomodulating effects, influencing several components of the immune system that participate in the pathology of EAE. As mentioned above, AFP caused reduced T-and B-lymphocyte reactivity together with altered antigen presentation and cell migration. The ability of a natural molecule such as AFP to exert such multi-level non-toxic activity, points to its potential use for the treatment of MS and other autoimmune and inflammatory disorders.
To summarize, we describe two novel strategies for coping with neuroinflammation: (1) Bifunctional compounds that enable multiple targeting and enhanced CNS permeability. The unique pharmacodynamic profile of these molecules renders them superior to combination therapy. ( 2) The use of AFP, a pregnancy-associated protein that exerts a multi-level effect on the various stages of EAE pathogenesis. Both strategies can be, and in the case of naturally occurring compounds are, utilized in many more clinical settings. Our data suggest that drug development productivity may be increased not only by 'reinventing the wheel', but also by a more judicious use of that which already exists.
